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Introduction: Large-cell neuroendocrine carcinoma is an aggressive variant of large-cell carci-
noma of the lung, which has poor survival in most series, resembling that of small-cell lung
carcinoma. We report our retrospective assessment of surgically-resected cases of both
tumours.
Methods: 33 large-cell neuroendocrine carcinomas and 16 peripheral small-cell lung carci-
nomas were reassessed retrospectively. Survival rates of both tumours in surgically-resected
cases were calculated and compared using KaplaneMeier survival curves and Log Rank test,
respectively.
Results: In large-cell neuroendocrine carcinomas, there were 25 patients with pathologic stage
I, 4 with pathologic stage II and 4 with pathologic stage III. In small-cell lung carcinomas, there
were 6 patients with pathologic stage I, 3 with pathologic stage II and 7 with pathologic stage
III. 12% of large-cell neuroendocrine carcinomas and 62.5% of small-cell lung carcinomas were
of advanced disease. The mean follow-up was 89 months. The actuarial survival for the 2
groups was not significantly different.
Conclusion: Large-cell neuroendocrine carcinomas of the lung have poor prognosis even in
early stages, with survival rates similar to that of small-cell lung carcinomas.
ª 2010 Elsevier Ltd. All rights reserved.2202520; fax: þ34942202520
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In this paper, we compare a series of surgically-resected
large-cell neuroendocrine carcinomas with another series
of surgically-resected small-cell lung carcinomas. We have
found a more advanced pathologic stage of the disease in
the second group but without actuarial survival differences.Introduction
Neuroendocrine lung neoplasms are a group of tumours that
share some morphological and biochemical characteristics,
such as the presence of dense cytoplasmic granules and the
ability to synthesise neuropeptides. In 1980, pulmonary
neuroendocrine tumours were categorised as typical carci-
noids, atypical carcinoids and small-cell lung carcinomas
(SCLC).1 However, some authors indicated that a fourth
category may exist between atypical carcinoids and SCLC in
prognosis.2,3 In 1991, Travis and colleagues4 proposed a new
category for large-cell neuroendocrine carcinoma (LCNEC)
and reported that its prognosis fell between atypical carci-
noids and SCLC. In 1999, the World Health Organization5
classified LCNEC as a variant of large-cell carcinoma. Its
cytologic features are identical to those of non-small-cell
carcinomas, but in addition, these tumour cells are positive
for neuroendocrine markers (chromogranin and synapto-
physin) or have neuroendocrine granules that are detected
by electron microscope. In 2004, Travis6 proposed a new
classification for neuroendocrine tumours with LCNEC and
SCLC among the high-grade malignity entities.
LCNEC is classified as a variant of large-cell carcinomas.
Although there is a report7 that referred to the prognosis of
patients with LCNEC as being the same as those with large-
cell carcinomas, most8e17 revealed that patients with
LCNEC had poorer prognoses, with 5-year survival rates of
15%e57%, and with clinical and biological features resem-
bling those of SCLC. This contrasts with the results of
Travis,4 who reported a prognosis between that of atypical
carcinoids and SCLC.
The purpose of this study is to report our experience
with resected LCNEC and peripheral SCLC, and in particular
to assess the differences between both regarding prognosis.Methods
A total of 38 large-cell neuroendocrine carcinomas of the
lung and 23 peripheral small-cell lung carcinomas were
selected from surgical specimens of the Surgical Pathology
archives of the Hospital Universitario Marques de Valdecilla
(Santander, Spain). These surgical specimens were
obtained from patients who underwent surgery from 1988
to 2005, and were reviewed by two experienced and inde-
pendent pathologists to verify the correct pathological
diagnosis, as described by Travis and colleagues: a mitotic
count of greater than 10 per 2 square millimetres.4 No
distinction was made between neuroendocrine differenti-
ation and neuroendocrine morphology, because no prog-
nosis difference was found in other studies.7,18 Five LCNEC
cases and seven SCLC were rejected because these were
widespread tumours (patients had simply undergonesurgery for pathologic diagnosis), or resection was less than
lobectomy, due to functional limitations. Thus, 33 LCNEC
and 16 peripheral SCLC, all early clinical stage and
completely resected tumours, remained for study. Clinical
charts were retrospectively studied in order to collect data
about epidemiology, manifestations, method of diagnosis,
clinical stage, treatment, pathologic stage, surgical
complications and follow-up details. When necessary,
patients or their families were telephoned if some piece of
information was not available on the clinical chart. In Table
1, some of these aspects are shown.
Statistical analysis
For the statistical analysis we used an SPSS package (SPSS
Inc, Chicago, IL). We used the KaplaneMeier survival curves
for calculating actuarial survivals and the Log Rank test to
see if the survivals were significantly different between
LCNEC and SCLC. In the survival analysis, the event
measured was death related to neoplastic disease.
This study requires no approval by the ethical committee
as it is a retrospective study and no patient names have been
revealed.Results
Pathology
In the LCNEC group, 3 pneumonectomies and 30 lobectomies
were performed. Stage distribution (Table 2) according to
the 1997 TNM system for classification of lung cancers19
showed 25 patients with pathologic stage I disease (6 T1N0,
19 T2N0), 4 with pathologic stage II (3 T3N0, 1 T2N1) and 4
with pathologic stage IIIa (1 T1N2, 3 T2N2). In the clinical
evaluation, no patient had N2 disease.
In the peripheral SCLC group, 5 pneumonectomies and
11 lobectomies were performed. In this group there were 6
patients with pathologic stage I disease (3 T1N0, 3 T2N0), 3
with pathologic stage II (1 T1N1, 2 T2N1), and 7 with
pathologic stage IIIa (1 T1N2, 4 T2N2, 2 T3N2) (Table 2). In
the clinical evaluation no patient had N1 or N2 disease.
In all patients, the clinical evaluation was a thorax e
upper abdomen CT and a PET-TAC. Peripheral negative
cases underwent resection without additional mediastinal
exploration. Patients with a positive PET-TAC exploration or
central tumours underwent EBUS, and if negative, media-
stinoscopy (both explorations are regarded as surgically-
explored mediastinum in Table 1).
Clinical data
All of the 33 patients with LCNEC and the 16 patients with
SCLCweremales, and therewere no females in these groups.
The average age at presentation was 64.91 in the LCNEC
group and 61.68 in the SCLC group. Both groups were
comparable for other prognostic factors, such as perfor-
mance status or clinical manifestations. Of the anatomically
resected tumours, 30were located on the right side and 19 on
the left side. At the time of presentation, 28 were asymp-
tomatic and the tumour was found incidentally on a chest
Table 1 General patient characteristics.
Pt Age Sex Stage PD FEV1 Resect Sympt DM SEM
1 63 M T1N1 SCLC 75% LN No BB Y
2 60 M N2 SCLC 80% LUL No BB N
3 62 M T2N0 LCNC 92% LUL No CTGB N
4 60 M T2N0 LCNC 102% LN Hem CTGB Y
5 56 M N2 LCNC 66% RLL No BB N
6 69 M T1N0 SCLC 93% LUL Hem IB Y
7 58 M N2 SCLC 82% RLL No BB N
8 66 M T2N0 LCNC 70% LLL No BB Y
9 59 M T1N0 LCNC 69% RUL No CTGB N
10 70 M T2N0 LCNC 104% RN Hem BB Y
11 55 M T2N1 SCLC 82% LLL No CTGB N
12 54 M T2N0 LCNC 93% RUL No SC Y
13 60 M T3N0 LCNC 97% RUL Pain CTGB N
14 61 M T2N0 LCNC 63% LLL No BB Y
15 45 M N2 LCNC 100% LN Cough CTGB Y
16 72 M T2N0 LCNC 90% RUL No IB N
17 73 M T2N0 LCNC 92% RUL Hem BB N
18 63 M T2N0 LCNC 99% LUL No SC Y
19 61 M T2N0 LCNC 94% LLL No BB Y
20 58 M T1N0 SCLC 88% LUL Hem IB Y
21 74 M T1N0 LCNC 90% RLL Hem CTGB N
22 61 M T3N0 LCNC 98% RUL Pain CTGB N
23 61 M N2 SCLC 99% RN No IB Y
24 69 M T2N0 LCNC 101% RLL No BB Y
25 57 M N2 SCLC 100% RLL LE BB N
26 64 M T2N0 LCNC 98% RUL Hem SC N
27 74 M T1N0 LCNC 83% LLL No IB Y
28 62 M T2N0 LCNC 86% RLL Hem BB Y
29 65 M T2N0 SCLC 90% RUL No BB Y
30 49 M T2N0 LCNC 105% RUL No CTGB Y
31 70 M T1N0 SCLC 78% RLL No CTGB Y
32 59 M N2 LCNC 99% RUL Hem BB N
33 65 M T1N0 LCNC 88% RLL Cough IB N
34 70 M T2N0 LCNC 54% RLL No SC Y
35 64 M N2 SCLC 67% LN Hem BB Y
36 58 M N2 SCLC 90% RLL No CTGB N
37 67 M T1N0 LCNC 95% RLL No IB N
38 64 M T2N1 SCLC 84% LN Hem BB Y
39 71 M T3N0 LCNC 97% RUL Hem CTGB Y
40 68 M T1N0 LCNC 85% LUL No BB N
41 63 M T2N0 LCNC 96% RLL Hem SC N
42 65 M T2N0 LCNC 75% RUL No BB Y
43 67 M N2 LCNC 59% LLL Hem IB N
44 62 M N2 SCLC 88% LN Hem CTGB Y
45 79 M T2N1 LCNC 96% LUL No CTGB N
46 73 M T2N0 LCNC 77% RUL Hem BB Y
47 59 M T2N0 SCLC 84% RUL No BB Y
48 64 M T2N0 SCLC 89% RLL No BB N
49 80 M T2N0 LCNC 91% RLL No BB Y
PtZ Patient; PD Z Pathological diagnosis; Resect Z resection; Sympt Z symptoms; M Z male; SCLC Z small-cell lung carcinoma;
LCNC Z large-cell neuroendocrine carcinoma; RUL Z right upper lobectomy; LUL Z left upper lobectomy; RLL Z right lower lobec-
tomy; LLLZ left lower lobectomy; LNZ left pneumonectomy; RNZ right pneumonectomy; HemZ haemoptysis; LEZ Lambert Eaton;
DM Z diagnosis method; SEM Z surgical exploration of the mediastinum; Y Z yes; N]No.
Neuroendocrine carcinomas of the lung 1931X-ray exam. In the other 21 patients, symptoms included: 16
haemoptysis, none of which was massive; 2 chest pain, both
with involvement of the chest wall; 2 non-productive
persistent cough; and one LamberteEaton syndrome ina patient with SCLC. There was no correlation between
asymptomatic or symptomatic presentation andpathological
stage, although the presentation of the unique case of
LamberteEaton syndrome in an N2 SCLC and the 3 patients
Table 2 TNM stages.
T1N0 T2N0 T1N1 T2N1 T3N0 N2 Total
LCNEC 6 19 0 1 3 4 33
SCLC 3 3 1 2 0 7 16
1932 J.M. Naranjo Go´mez, J.J. Go´mez Roma´nwith pain in the T3N0 cases should be noted. In the LCNEC
group, non-small-cell lung carcinoma diagnosis was deter-
mined with bronchoscopic biopsy in 13 patients, with
computed tomography-guided biopsy in 10 patients, with
sputum cytology in 5 patients and with intraoperative biopsy
in another 5 patients. None of these patients had been
diagnosed as LCNEC before referral. Regarding SCLC, diag-
nosis was suggested with bronchoscopic biopsy in 9 patients,
with computed tomography-guided biopsy in 4 patients and
with intraoperative biopsy in another 3 patients. All of them
were peripheral tumours.
All 49 patients proceeded to thoracotomy and were
anatomically resected, 8 with pneumonectomy and 41 with
lobectomy. Each patient had systematic nodal dissection at
the time of resection. In the LCNEC group, no patient under-
went induction chemotherapy. No patient with T3N0 disease
underwent adjuvant therapy because the tumour was
completely resected. The N1 and N2 positive patients under-
went cisplatin-based adjuvant chemotherapy. T2 N0 cases
were not treated with chemotherapy because at that time it
was not considered for that stage. All patients with SCLC
underwent cisplatin-based adjuvant chemotherapy, medias-
tinum radiotherapy and prophylactic cranial irradiation.
Follow-up data
The follow-up for these patients ranged from 26 months to
179 months with a median follow-up time of 89 months. In
an LCNEC patient and in another SCLC patient, it was not
possible to determine the survival status. Of the remaining
47 patients with complete follow-up, 10 were alive and
disease free at the moment of review: 9 LCNEC, at 26
months (stage T1N0), 36 months (stage T1N0 and T2N2), 42
months (stage T2N0), 51 months (stage T2N0), 55 months
(stage T1N0), 71 months (stage T2N0), 72 months (stage
T2N0) and 143 months (stage T2N0); and 1 SCLC, at 45
months (stage T1N0). Two patients with LCNEC (stage T2N0)
had died at 1 and at 55 months of causes other than
neoplastic disease. Another 4 patients with SCLC had died
at 2 months (stage T2N0), 6 months (stage T2N1), 42 months
(stage T1N0) and 127 months (stage T1N0) of causes other
than neoplastic disease. All of them were disease-free. The
remaining 21 LCNEC patients and 10 SCLC patients had died
from recurrence of their disease. These data are summar-
ised in Table 3.Table 3 Follow-up.
LCNEC
Alive without illness 9 (26e143 m): 8 stage I, 1 stage
Dead due to other illness 2: 1 and 55 m. Stage I
Dead due to relapse 21
Missing 1In the LCNEC patient group, the overall survival was 70%
at 1 year, 46% at 3 years and 42% at 5 years. For the
accurately-staged cases, actuarial 5-year survival rate was
53% for the 25 stage I patients (50% for T1N0 stage, 56% for
T2N0 stage), 0% for the 4 stage II patients, and 25% for the 4
stage IIIa patients. For non-stage I patients, 5-year survival
was 12%. In the SCLC group, overall survival rate was 46% at
1 year and 31% at 3 years, which held true at 5 years. For
the accurately-staged cases, actuarial 5-year survival was
60% for the 6 stage I patients, 66% for the 3 stage II patients,
and 0% for the 6 stage IIIa patients. For non-stage I patients,
the 5-year survival rate was 13%.
The overall actuarial survival rate of both groups was
compared and there was no significant survival difference
in Log Rank analysis (p Z 0.54) (Fig. 1). When we analysed
individual pathological stages (I, II, III and non-stage I) we
found no significant differences either (Figs. 2e5).
Discussion
The classification of neuroendocrine lung tumours has been
subjected to considerable controversy in the past, resulting
in multiple classifications, the latest established in 2004.6
Several entities are included in this spectrum, from the
low-grade typical carcinoids to the intermediate-grade
atypical carcinoids and the high-grade categories with
large-cell neuroendocrine carcinomas (LCNEC) and small-
cell lung carcinomas (SCLC). LCNEC differs from typical and
atypical carcinoids in terms of its greater quantity of
mitosis and abundant necrosis, while it differs from SCLC
exclusively in terms of its cytologic characteristics.20 These
two high-grade tumours are not always easily differentiated
by pathologists.21,22 While there is no doubt about the
better prognosis of low-grade neuroendocrine tumours in
comparison to high-grade neuroendocrine tumours, and of
typical carcinoids in comparison to atypical carcinoids,
there are several studies revealing a similar prognosis for
LCNEC and SCLC.8,10,11,14,15,20 Some authors go even
further, suggesting that LCNEC and SCLC be classified into
one group, called “high-grade malignant neuroendocrine
tumours”.9
In the present study, we have found one difference
between the two tumours: both groups of tumours were
studied preoperatively in the same way, as previously
described, but while 88% of the LCNEC resected had early
disease (pathologic stage I or II), only 37% of SCLC did (path-
ologic stage I). Authors agree that the role of surgery in
peripheral SCLC should be limited to those with stage I
disease27. If we assess only mediastinal nodes and exclude
hilar ones, 12% of non-N2 LCNEC disease in the clinical eval-
uation had mediastinal involvement, contrasting with 44% of
SCLC. Both groups were subjected to the same criteriaSCLC Total
IIIa (36 m) 1 (45 m): stage I 10
4 (2e127 m): 3 stage I, 1 stage II 6
10 31
1 2
Figure 1 KaplaneMeier survival estimates for both groups comparing survival between large-cell neuroendocrine carcinoma
(continuous line) and small-cell lung carcinoma (discontinuous line) (Log Rank test; p Z 0.54 not significant).
Neuroendocrine carcinomas of the lung 1933to undergo surgical exploration of the mediastinum, and in
both groups there were true and false negative cases
(1 LCNEC vs. 3 SCLC) cases. Therefore, we can affirm that,
according to our results, SCLC have more probabilities thanFigure 2 KaplaneMeier survival estimates for stage I patients co
(continuous line, 25 patients) and small-cell lung carcinoma (di
significant).LCNEC of spreading to the mediastinal nodes without having
been detected in the preoperative evaluation. Most N2 cases
in both groups did not undergo surgical exploration of the
mediastinum. Perhaps every patient should undergo suchmparing survival between large-cell neuroendocrine carcinoma
scontinuous line, 6 patients) (Log Rank test; p Z 0.49 not
Figure 3 KaplaneMeier survival estimates for stage II patients comparing survival between large-cell neuroendocrine carcinoma
(continuous line, 4 patients) and small-cell lung carcinoma (discontinuous line, 3 patients) (Log Rank test; pZ 0.42 not significant).
1934 J.M. Naranjo Go´mez, J.J. Go´mez Roma´nexploration before resection, although false negatives do
exist.
When survival was analyzed, no statistical differences
were found between the groups, either globally or in the
different stages. The size of our groups is small, but these
findings are similar to what has been described by other
authors.8,10,11,14,15,20 Because in stages II and IIIa there wereFigure 4 KaplaneMeier survival estimates for stage III patients co
(continuous line, 4 patients) and small-cell lung carcinoma (discontinotmany cases, we decided to group them, but survival again
was similar in both tumours. Surprisingly, and as stated
previously, overall survival was similar in both neoplasms,
despite there being a higher percentage of cases with stage I
disease in theLCNECgroup than in theSCLCgroup. Buteven in
stage I, we found poor survival for LCNEC (53%), as had other
authors9,11,12,14e17whodescribe 5-year survival rates of 27%emparing survival between large-cell neuroendocrine carcinoma
nuous line, 7 patients) (Log Rank test; pZ 0.10 not significant).
Figure 5 KaplaneMeier survival estimates for non-stage I patients comparing survival between large-cell neuroendocrine
carcinoma (continuous line, 8 patients) and small-cell lung carcinoma (discontinuous line, 10 patients) (Log Rank test; pZ 0.60 not
significant).
Neuroendocrine carcinomas of the lung 193567%. Nevertheless, this is in contrast to what was reported by
Zacharias et al.,18 who described a survival rate of 88% at 5
years for stage I disease. They explain that complete resec-
tion and systematic nodal dissection make this outcome
possible, althoughwehave followed this sameapproach, too.
Because of the aggressive nature of LCNEC, postoperative
chemotherapy or radiotherapy have been used in several
studies published about this tumour, and no advantages in
survival have been found in any of the trials.15,21,23,24 On the
other hand, adjuvant chemotherapy is effective for patients
with non-small-cell carcinomas25e27 and patients with path-
ologic stage IB or higher should be likewise treated. There-
fore, LCNECpatients inadvanced stages shouldperhapsnotbe
an exception. In a study by Iyoda and colleagues,13 they found
a comparable survival of stage I patients with LCNEC at 62%
after more than 5 years. In a subgroup of 5 patients who had
stage I disease and adjuvant chemotherapy, survival was 100%
at 5 years. However, this beneficial effect of adjuvant
chemotherapywas not observed in non-stage I patients. Iyoda
et al.,17 in another study, demonstrated poorer survival rates
in pathologic stage IA LCNEC patients when compared to
patients with adenocarcinomas or squamous cell carcinomas
in the same pathologic stage. Multivariate analysis revealed
that LCNEC was a significant negative prognostic factor, so
authors concluded that patients with LCNEC, even in stage IA,
should have adjuvant therapy, just as patients with SCLC. The
effectiveness of prophylactic cranial irradiation for patients
with LCNEC is not clear. There are trials for advanced non-
SCLC, but up tonow it is not a standardoption.28However, this
improves both overall survival and disease-free survival in
patients with SCLC,29 and it could be promising among
patients with LCNEC.In conclusion, we have found a greater propensity
towards occult lymphatic cancer spreading during clinical
evaluation in peripheral SCLC, when compared to LCNEC.
However, this has not translated into poorer survival rates.
Patients with resected LCNEC have proved to have survival
rates similar to those of patients with resected SCLC,
globally and in the different pathologic stages. Even in
stage I, patients with LCNEC have poor survival, compa-
rable to that published by most authors, and not statisti-
cally different from the survival of patients with SCLC in the
same stage. This study, however, has an important limita-
tion: the small size of our groups. In the review of the
literature, the role of adjuvant therapy has not been
adequately determined. A multicentre, prospective, rand-
omised control trial is necessary to answer this question,
especially in stage I, and to clarify the absence of differ-
ences in survival between SCLC and LCNEC that we have
found.
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